Kevin M. Pantalone, DO, ECNU, FACE

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time in range for adults with type 2 diabetes, researchers reported.

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to topline results from a phase 3a trial.

Among patients with diabetes, the teach-back method was associated with better interactions with health care providers, more engagement in shared decision-making and a greater likelihood of receiving lifestyle advice, data show.

Older adults with an HbA1c in the prediabetes range were far more likely to revert to normoglycemia or die during 5-year follow-up than to progress to overt type 2 diabetes, according to a community-based study.

Prescribing combination therapy to individuals with diabetes early in treatment could allow for better glycemic control and reduced odds of treatment failure, according to a speaker at the virtual Cardiometabolic Health Congress.

Treatment with dapagliflozin significantly reduced renal failure, cardiovascular death or hospitalization for heart failure, and prolonged survival among adults with chronic kidney disease with and without type 2 diabetes, study data show.

Adding liraglutide to metformin may help reduce the risk for developing type 2 diabetes vs. metformin alone for women with gestational diabetes, according to findings published in the Journal of Diabetes and its Complications.

Prediabetes was less likely to progress to type 2 diabetes among adults who took a combination of linagliptin and metformin vs. metformin alone; the combination group was also more likely to achieve normal glucose levels, according to findings published in Metabolism.

Insulin is needed less frequently and HbA1c is lowered more robustly when adults with type 2 diabetes do not delay combination therapy but begin treatment by taking sitagliptin and metformin together, according to findings published in Diabetic Medicine.

CHICAGO — When treating patients with type 2 diabetes, physicians may have more success if they use simultaneous combination therapy immediately rather than following the traditional stepped-up method of waiting to intensify treatment, according to a speaker at the Cardiometabolic Health Congress.